| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705291 | Ophthalmology | 2017 | 11 Pages |
Abstract
In this phase IIb clinical trial, a 62% relative benefit from baseline was noted in the E10030 1.5Â mg combination therapy group compared with the anti-VEGF monotherapy group. A favorable safety and efficacy profile of E10030 combination therapy for nAMD was evident across multiple clinically relevant end points. This highly powered study provides strong rationale for a confirmatory phase III clinical trial.
Keywords
CNVETDRSnAMDPDGFRPEiOpSHRMChoroidal neovascularizationfluorescein angiographyretinal pigment epitheliumOctOptical coherence tomographyVisual acuityearly treatment diabetic retinopathy studyneovascular age-related macular degenerationadverse eventVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)platelet-derived growth factorIntraocular pressuredisc areasubretinal hyperreflective material
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Glenn J. MD, Thomas A. MD, MBA, Antonio P. MD, Francois MD, Pravin U. MD, Chiara M. MD, Harvey MD, Jordi MD, PhD, Joel A. MD, PhD, Maddalena MD, Federico MD, Keith MBA, Samir C. MD,